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BACKGROUND: Preoperative anemia in patients
undergoing elective hip and knee arthroplasty is associated with increased postoperative morbidity and mortality, red blood cell (RBC) transfusion, and length of stay (LOS). The aim of this study was to assess the effect of optimizing hemoglobin (Hb) levels before elective primary hip and knee arthroplasty.
STUDY DESIGN AND METHODS:
This is a prospective comparative cohort study of patients who underwent elective hip and knee arthroplasty before (control) and after (intervention) the launch of a Hb optimization program. Patients with anemia followed an agreed upon algorithm dependent on their medical history and blood variables taken on listing for surgery. The primary outcome for this study was the requirement for allogenic RBC transfusion. Secondary outcomes included hospital LOS, admission to critical care, readmission, medical complications, incidence of thromboembolic events, mortality, and costs. 9 [0.5%], p 5 0.030). LOS was significantly reduced from 3.9 days to 3.6 days (p 5 0.017). The saving for the cohort was £263,000 ($342,000).
RESULTS:
CONCLUSIONS: Algorithm-led preoperative anemia screening and management in elective arthroplasty was associated with reduced RBC transfusion, readmission, critical care admission, LOS, and costs. P reoperative anemia in patients undergoing elective total hip and knee replacement has been associated with increased transfusion, 1 length of stay (LOS), 1,2 and postoperative complications. 1, 3, 4 Over the years different methods have been applied in an attempt to reduce blood loss and improve outcomes such as the use of tranexamic acid [5] [6] [7] and the implementation of enhanced recovery programs. 8 It has been suggested that preoperative blood management improves outcomes. [9] [10] [11] [12] New guidelines suggest that preoperative blood management in patients undergoing elective surgery should be a routine activity in the national health service (NHS). 9, 13 This study aims to evaluate the impact of an algorithm for preoperative anemia screening and intervention in elective primary hip and knee arthroplasty.
Algorithm development
The algorithm was designed for use within an NHS setting and was led by a hematologist with hematology and pharmacy colleagues based on available evidence, including an existing published algorithm. 10 The protocol was further refined with engagement with anesthetic groups and orthopedic surgeons. Finally patient and general practitioner groups contributed, particularly to the referral pathway and patient literature. The mainstay of treatment was oral iron as shown in Fig. 1 . Patients on oral iron treatment received 200 mg of ferrous sulfate three times a day for 28 days. At the time of writing and designing the protocol it was decided to use standard dosing of iron for iron deficiency as recommended in the British National Formulary. This facilitated prescribing protocols and community administration and was standard practice at the time. Intravenous (IV) iron therapy was used when appropriate, taking into account reduced renal function (estimated glomerular filtration rate < 50 mL/hr), patients' wishes, and allergies. Patients weighing less than 50 kg received 500 mg of ferric carboxymaltose and patients more than 50 kg received 1000 mg of ferric carboxymaltose in 250 mL of 0.9% sodium chloride over 30 minutes (Ferinject, Vifor Pharma UK Limited). This was administered in hospital as an outpatient.
MATERIALS AND METHODS
This is a prospective observational cohort study where two series of primary elective hip and knee arthroplasties were compared. Each patient underwent our previously published enhanced recovery program.
14 Briefly, this encompassed preoperative patient education, a light general anesthetic or low-dose spinal anesthesia with sedation, IV tranexamic acid (30 mg/kg, maximum 2.5 g;
Cyclokapron injection, Pfizer) at the start of anesthesia, unless contraindicated, prophylactic IV antibiotics, 0.125% levobupivicaine local anesthetic infiltration to the surgical site, regular oral analgesia, and early mobilization. Contraindications for IV tranexamic acid include a cardiac event, cerebrovascular accident, pulmonary embolism (PE), or deep vein thrombosis (DVT) within the past 6 months, a known history of a thrombotic disorder, coronary stents, allergy to tranexamic acid, disseminated intravascular coagulation, active cancer, and overt hematuria. Patients received low-molecular-weight heparin administered as prophylaxis for venous thromboembolism. Before the algorithm introduction, patients would be referred back to their primary care doctor for investigation if the hemoglobin (Hb) levels at the preoperative assessment were below 10.0 g/dL. No organized algorithm existed for anemic patients above this threshold. The control group was comprised of patients undergoing primary total hip replacement (THR) or total knee replacement (TKR) from February 2012 to January 2013. In February 2013 we launched the anemia screening and intervention program with surgical teams requested to refer all patients listed for primary joint replacement. All patients screened for anemia who underwent a THR or TKR between February 2013 and May 2014 were included in the intervention group. Anemia was defined as a Hb of less than 12.0 g/dL for females and of less than 13.0 g/dL for males, as per World Health Organization definitions. 15 Routine preoperative blood samples (including full blood count, ferritin levels, urea and electrolytes, glomerular filtration rate, liver function tests, and erythrocyte sedimentation rate) were taken in the outpatient clinic at the point of listing for surgery and results were followed up and acted upon according to the algorithm in Fig. 1 . Our ferritin cutoff was designed to be pragmatic and easily assessed on protocol bearing in mind that interpretation of ferritin levels can be difficult in inflammatory conditions. We ensured that any patient with definite iron deficiency (ferritin below normal range) was further assessed for causes. Intermediate levels of ferritin were assessed with the erythrocyte sedimentation rate and the patient's history to determine next actions.
Liver function tests and erythrocyte sedimentation rate blood tests supported decision making when cases were referred to the hematologist. Erythrocyte sedimentation rate values were calculated dividing the age by 2 for men and age 110 divided by 2 for women. 16 The median waiting time for surgery was 64 days in the control group and 59.5 days in the intervention group. The primary outcome for this study was the requirement for allogenic red blood cell (RBC) transfusion within 30 days of elective primary hip or knee arthroplasty. Secondary outcomes included length of hospital stay, admission to critical care, readmission with overnight stay for any reason, the incidence of DVT and PE within 60 days, and 30-and 90-day mortality. Medical complications (including stroke [cerebrovascular accident], myocardial infarction [MI], gastrointestinal bleeding [GIB]) occurring within 30 days of surgery were also included. The effect of the intervention on preoperative Hb levels for those patients identified as anemic on screening was studied.
The institution blood transfusion policy during this study was unchanged. A transfusion was triggered with an Hb level of 8.0 g/dL or less or between 8.0 and 10.0 g/dL if the patient was symptomatic after hospital policy and national guidelines. 17 Hospital discharge criteria can be seen in Table 1 .
Data collection and statistical analysis
Patient demographics (age, sex, surgery type) and comorbidities (hypertension, insulin and non-insulin-dependent diabetes mellitus, atrial fibrillation, ischemic heart disease, and chronic obstructive pulmonary disease) were collected by professional medical coders. Postoperative complications including cerebrovascular accident, MI, GIB, return to theater (RTT), and the diagnosis of postoperative DVT or PE within 60 days were recorded by professional medical coders. The incidence of death within 30 and 90 days postsurgery was obtained via hospital linkage to the Office for National Statistics. Postoperative LOS (defined as midnights in hospital) and readmission to hospital within 30 days of surgery was reported by hospitals' patient administration system.
Hemoglobin levels preoperatively and on Day 1 postoperatively were retrieved from the trust pathology results system (ICE; Sunquest Information Systems [Europe] Ltd.). Blood transfusion data was obtained from the Trust blood transfusion service database.
Statistical analysis was supported by computer software (IBM SPSS Statistics, Version 21, IBM Corp.). Data for LOS, age, and Hb level were normally distributed, met parametric assumptions, and so were summarized in terms of the mean, while data for transfused units were nonnormally distributed and summarized using the median. Pearson's chi-square test (for frequency data), Mann-Whitney U test (for nonparametric/ordinal data), and unpaired t test (for continuous parametric data) were used for inferential analyses. For comparison of frequency data Fisher's exact test was used when the expected count was less than 5 in any cell. The paired t test was used for comparison of Hb before and after intervention in anemic patients. Multivariable logistic regression was used to determine whether being in the intervention cohort was independently associated with the need for postoperative blood transfusion after adjusting for the effects of the demographic and preoperative clinical characteristics of the cohort. Significant bivariate predictors were identified and these were then considered for inclusion in the final model. Model building used stepwise methods based on backward elimination and model robustness and fit were checked by examination of residuals, eigenvalues, and tolerance. p values of less than 0.05 were considered significant and two-sided tests employed throughout.
RESULTS
Full intervention and control cohort data set
The prescreening cohort comprises a total of 1814 procedures that received a primary total hip or knee replacement from February 2012 to January 2013. The intervention cohort includes 1622 procedures between February 2013 and May 2014.
The demographic and preoperative clinical characteristics of both cohorts were compared (Table 2 ) and are similar. The intervention cohort had higher prevalence of existing ischemic heart disease and hypertension, and other comorbidities were similar.
A total of 132 patients in the intervention cohort received iron treatment. When patients received iron treatment their mean Hb level increased 0.5 g/dL (mean pretreatment Hb level, 11.8 g/dL; standard deviation [SD] 6 6.837; mean posttreatment Hb level, 12.3 g/dL; SD 6 7.965; t 5 5.584, p < 0.001).
Postoperative outcomes were recorded (Table 3 ). In the control cohort, 108 patients (6.0%) required RBC transfusion within 30 days of surgery, 81 THR (10.2%) and 27 TKR (2.7%). After implementation of the intervention, there was a significant reduction in transfusion rate to 3.9%. A total of 66 patients were transfused in the intervention group, 52 THR (6.9%) and 14 TKR (1.6%). Postoperative deep infection rates were 0.9% for the control group and 0.5% in the intervention group. The intervention was also associated with the following significant improvements: LOS reduced from 3.9 days to 3.6, admission to critical care reduced from 1.3% to 0.6%, and readmission reduced from 4.5% to 3.0%. Postoperative medical complications within 30 days of surgery remained similar (Table 3) .
In multivariable logistic regression analysis, RBC transfusion within 30 days of surgery was independently associated with being in the control group (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.06-2.08; p 5 0.021) after controlling for the effects of other significant independent demographic and preoperative clinical variables: lower preoperative Hb level (OR, 0.91; 95% CI, 0.90-0.92; p < 0.001) and an existing diagnosis of ischemic heart disease (OR, 1.81; 95% CI, 1.12-2.93; p 5 0.016).
In bivariate analyses within the intervention group (see Table 4 ), requiring RBC transfusion within 30 days of surgery was significantly associated with greater age, being female, having a THR, low preoperative Hb, readmission within 30 days, RTT, PE within 60 days, and postoperative LOS.
Age, sex, and type of operation were significantly associated with postoperative transfusion. Transfused patients had a significantly increased postoperative LOS, postoperative Hb levels, readmission, and postoperative PE within 60 days (Table 4) . 
Intervention and control cohort subjects with anemia
There were a total of 196 anemic patients in the intervention group (12.9%). A total of 120 patients (61.2%) received oral iron treatment and 12 patients (6.1%) IV iron. The remaining 64 patients (32.7%) were referred back to the primary care doctor or hematologist for further investigations. When comparing preoperative anemic patients in both cohorts we observed that those in the intervention group had significantly less RBC transfusions and critical care admission (p 0.001 and p 5 0.007, respectively) and a trend toward reduced LOS. There was no increased risk of postoperative complications (Table 5) .
There was a reduction in postoperative LOS among the patients with anemia, from 6 days in the control group to 4.9 days, although it was nonsignificant. When examining the postoperative LOS among the nonanemic patients between cohorts there was no difference (3.58 days in the control group and 3.45 days in the intervention group; p 5 0.234).
Cost analysis
The overall cost and savings of implementing anemia screening and treatment program can be seen in Table 6 . The cost of iron replacement in our study was £3, 164 . The postoperative LOS between the anemic patients of both cohorts was from 6 to 4.9 days and the overall reduction in both cohorts was significantly reduced from 3.9 to 3.6 days. That translates to a total annual saving of 649 days (£259,000 [$337,000] as each elective orthopedic bed has a cost of £400 [$520.40], as per Trust finance department information). The total savings in our unit was £266,000 ($346,000) in this cohort after we introduced the intervention. The implementation of the anemia screening and treatment program cost £28.98 ($37.70) per patient, but saved £191.47 ($249.10) per patient producing an overall saving of £162.46 ($211.36) per patient. In a trust of our size (approx. 2500 primary hip and knee replacements) complete algorithm compliance translates to an annual saving of £406,000 ($528,000) for patients undergoing primary hip or knee replacement. This excludes potential savings from reduced readmissions.
DISCUSSION
Preoperative anemia in patients undergoing major elective orthopedic surgery is associated with increased postoperative complications. 1, 3, 18 Over the years efforts have been made to combine blood management modalities to improve patient outcomes and reduce blood transfusion and its associated risks. 19 Almost two decades ago it was demonstrated that preoperative iron treatment in patients undergoing joint replacement surgery was effective in reducing the decrease in postoperative Hb. 20 Recent studies suggest the need for combining blood management modalities to reduce transfusion rates and improve patient outcomes. 1, 19, 21 Sinclair and colleagues 22 showed that cell salvage and preoperative autologous blood donation would significantly reduce the requirements for postoperative allogenic blood transfusions but it was associated with great costs. Gonzalez-Porras and colleagues 23 compared several methods to increase preoperative Hb including oral and IV iron treatment and found them effective in reducing postoperative transfusion. They concluded that individualized preoperative blood management treatment is effective at reducing blood cell transfusion but no information regarding costs is given. Muñoz and coworkers 24 recently published a series of 2547 patients confirming the effective use of preoperative IV iron in major orthopedic surgery. The Network for Advancement of Transfusion Alternatives (NATA) published blood management guidelines in 2011 for elective orthopedic surgery. 12 They suggest a complex algorithm with treatment options including oral and IV iron as well as erythropoiesis-stimulating agent therapy and folic acid and vitamin B12 therapy. Our algorithm included only two modalities of treatment, oral and IV iron, but did include a group who needed further investigations. We found both efficient at effectively reducing blood cell transfusion and improving LOS, critical care admission, and readmission while being cost-effective. The NATA algorithm suggests screening patients at least 28 days before surgery. In our unit we screen at the time of listing for surgery, which is normally approximately 60 days. Patients can complete treatment while on the list when appropriate or can be referred back to the primary care doctor for further investigations minimizing theater cancellations. The efficacy of NATA algorithm has not yet been clinically proven to be successful. Other algorithms have been published in an effort to reduce transfusion in patients undergoing major orthopedic surgery including Kotz e and colleagues in 2012. 10 In their algorithm they used erythropoietin (EPO)-we had concerns about side effects, and practicalities, and we did not include the routine use of EPO in our protocol. No patients in our cohort received EPO. In addition a multicenter randomized controlled trial found the use of EPO 25 and was associated with a higher risk of postoperative thromboembolic events, 26 although the trial used EPO alone rather than with IV iron supplementation. As well as oral and IV iron treatment, Kotz e and coworkers also additionally used perioperative tranexamic acid in the intervention group, which may have influenced outcomes. In addition they treated nonanemic patients with oral or IV iron if the ferritin level was low, and further research is needed on this group. A systematic review has shown that nonanemic iron deficiency patients with low ferritin (<16 mg/L) may benefit from investigation and treatment. 27 Although there were no strictly nonanemic iron deficiency patients, the intervention group in our study includes patients with mild anemia and ferritin between 12 and 100 mg/L and our algorithm has shown improvement in patient outcomes. Our guidelines ensured that anyone with established iron deficiency was referred to the primary care doctor for appropriate investigation. They observed a significant reduction of RBC transfusion, LOS, and readmission, and our data corroborate these findings. We also observed a significant reduction in critical care admissions that is not reported in the article by Kotz e. In addition we selected the smallest group (6.1%) for treatment with IV iron due to specific patient criteria. In 2015, Kotz e again published guidelines on the identification and management of preoperative anemia, suggesting necessary pathways to ensure anemia screening and correction before surgery as well as methods for treatment including oral and IV iron supplements. 9 Our algorithm was given as an example. We found a relationship between transfusion and poor outcome with increased LOS, readmission, and postoperative pulmonary emboli events. Transfusion was also most frequent in females and THR likely due to lower preoperative Hb in females and larger blood loss in THR. These findings support those of other literature. 1, 10, 28 Despite the potency of the intervention in terms of outcomes, the actual improvement in Hb levels post iron treatment was modest at a mean of 0.5 g/dL. We could speculate that these patients were better primed for surgery and able to respond to blood loss-perhaps having their iron stores corrected, and in addition Hb could have been improved further after the second blood test. We had 120 patients receiving oral iron. We did not formally assess the compliance or tolerability in these patients but Tolkien and colleagues 29 reported high gastrointestinal side effects in patients receiving oral iron supplementation. Future algorithms modifications are likely to have a higher reliance in IV iron to improve tolerability, compliance, and Hb levels. 29, 30 With the introduction of the anemia screening and preoperative treatment algorithm we significantly reduced the transfusion rate with an overall savings of 121 units of donated blood. This not only has an economic impact for the health care system but also for patients in terms of reducing the risk of transfusion-related complications and LOS. In addition it allows scarce supplies of donated blood to be used elsewhere.
Although patients in the intervention group were marginally older, and had a higher prevalence of ischemic heart disease as well as chronic obstructive pulmonary disease, this is likely to be due to improving diagnosis at primary care level compared to the control group. We have also noted a similar effect in previous studies where the intervention group appears to have a higher prevalence in these comorbidities. 8 There are elements of our data that require further explanation. We found a significant reduction to RTT in patients in the intervention group compared to those in the control group (15 vs. 3) but this cannot be attributed to the anemia intervention program as the number of preoperatively anemic patients that returned to theater within 30 days was the same in both cohorts. (2 vs. 2). Although our preoperatively anemic patients had the biggest reduction in LOS with the intervention, there was also a modest reduction seen in nonanemic patients who had no change to their pathway. This could be due to unrelated reasons such as better discharge systems or to a herd effect where fewer patients stayed longer periods and the whole cohort were discharge more quickly. Similar reductions in LOS had been achieved with other preoperative protocols using EPO and IV iron as a treatment. 24, 31 The implementation of the algorithm not only has improved patient care, reducing LOS and postoperative transfusion rates and complications, but also has significantly reduced cost. In a trust of our size, the net savings per annum amount to £406,000.
The study has some limitations: Data on patients receiving tranexamic acid were not collected, although in our Trust all elective arthroplasty surgery routinely received tranexamic acid on induction unless contraindicated as previously stated and it is likely that these contraindications affected a small proportion of patients. Also due to the large number of patients in this study a similar proportion of them in each arm would have received tranexamic acid at the time of surgery. We were not able to take into account the costs of the primary care investigations; therefore, the overall savings might be reduced, although readmissions, also not costed, are likely to offset this. When analyzing the LOS we did not exclude outliers, and when analyzed separately, reduction in LOS was not significant in either subgroup (p 5 0.092, for anemic patients; p 5 0.234 for nonanemic patients). We are keen to present real-world pragmatic results where outliers will occur.
Our algorithm has been proven effective in elective primary hip and knee replacement. It seems likely the algorithm could be employed in other similar orthopedic procedures, and possibly other specialties, but further studies will be required. This preoperative anemia algorithm for elective primary hip and knee arthroplasty has been shown to be safe and is associated with a reduction in RBC transfusion, readmissions, critical care admission, LOS, and hospital costs.
